Possible prospects for the combined administration of antidepressants and antioxidants in neurological patients

Antidepressants (ADs) are a group of drugs whose action primarily consists of stimulating neurotransmitter systems (dopaminergic, serotonergic and noradrenergic systems). Neurologists prescribe them for the treatment of post-stroke and other depression, chronic pain syndromes, neuropathic pain, panic attacks, correction of post-Covid syndrome, for the prevention of migraines, Parkinson’s disease and neurodegenerative diseases, including Alzheimer’s disease. However, even with appropriate therapy, many people with depressive disorder may experience subsyndromal symptoms and complete remission is short-lived, so there is a need to use other therapeutic approaches. Combining two or more antidepressants may target different neurochemical pathways while increasing the risk of side effects and the development of resistance. Therefore, the search for alternative treatments is urgent, and oxidative stress appears to be an interesting therapeutic target. The combined use of AD and antioxidants may provide an effective and safe approach to enhancing antidepressant effects by synergistically enhancing certain antidepressant activities (eg, enhancing monoamine reuptake inhibition) or by additive pharmacological effects, such as adjusting neurotransmitters and reducing the damaging effects of active agents. forms of oxygen. There are a number of clinical studies to prove the effectiveness of the combined use of antioxidants and antioxidants. In the group of patients receiving a combination of antioxidants and antidepressants/anti-anxiety drugs, there was a better regression of symptoms and severity of depression, which probably indicates the usefulness of adjuvant antioxidant therapy with regular psychotropic treatment. The use of combination drugs in complex therapy with blood pressure seems to be a promising direction and requires further study.

1. Parfenov VA. The use of antidepressants in neurological practice. Neurology, Neuropsychiatry, Psychosomatics. 2023;15(2):4–9. (In Russ.) https://doi.org/10.14412/2074-2711-2023-2-4-9.

2. Romanov DV, Petelin DS, Volel BA. Depression in neurological practice. Meditsinskiy Sovet. 2018;(1):38–45. (In Russ.) https://doi.org/10.21518/2079-701X-2018-1-38-45.

3. Sarris J, Murphy J, Mischoulon D, Papakostas GI, Fava M, Berk M, Ng CH. Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. Am J Psychiatry. 2016;173(6):575–587. https://doi.org/10.1176/appi.ajp.2016.15091228.

4. Mosolov SN, Malin DI, Ryvkin PV, Sychev DA. Psychotropic Drugs Interaction. Current Therapy of Mental Disorders. 2019;(S1):2–35. (In Russ.) https://doi.org/10.21265/PSYPH.2019.50.40828.

5. Kotzaeroglou A, Tsamesidis I. The Role of Equilibrium between Free Radicals and Antioxidants in Depression and Bipolar Disorder. Medicines (Basel). 2022;9(11):57. https://doi.org/10.3390/medicines9110057.

6. Putilina MV. Anxiety- depressive disorders and stroke: possible etiopathogenetic correlations. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2014;114(6):86–92. (In Russ.) Available at: https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-ims-s-korsakova/2014/6/031997-72982014616.

7. Bhatt S, Nagappa AN, Patil CR. Role of oxidative stress in depression. Drug Discov Today. 2020;25(7):1270–1276. https://doi.org/10.1016/j.drudis.2020.05.001.

8. Mazloom Z, Ekramzadeh M, Hejazi N. Efficacy of supplementary vitamins C and E on anxiety, depression and stress in type 2 diabetic patients: a randomized, single-blind, placebo-controlled trial. Pak J Biol Sci. 2013;16(22):1597–1600. https://doi.org/10.3923/pjbs.2013.1597.1600.

9. Putilina MV, Fedin AI. Post-stroke depression, possibilities of therapy in patients in the acute period of stroke. Atmosfera. Nervnye Bolezni. 2005;(1):6–9. (In Russ.) Available at: https://atmosphere-ph.ru/modules/Magazines/articles/nervo/an_1_2005_06.pdf.

10. Burtscher J, Niedermeier M, Hüfner K, van den Burg E, Kopp M, Stoop R et al. The interplay of hypoxic and mental stress: Implications for anxiety and depressive disorders. Neurosci Biobehav Rev. 2022;138:104718. https://doi.org/10.1016/j.neubiorev.2022.104718.

11. McGarry T, Biniecka M, Veale DJ, Fearon U. Hypoxia, oxidative stress and inflammation. Free Radic Biol Med. 2018;125:15–24. https://doi.org/10.1016/j.freeradbiomed.2018.03.042.

12. Zhou S, Chen R, She Y, Liu X, Zhao H, Li C, Jia Y. A new perspective on depression and neuroinflammation: Non-coding RNA. J Psychiatr Res. 2022;148:293–306. https://doi.org/10.1016/j.jpsychires.2022.02.007.

13. Gorlova A, Svirin E, Pavlov D, Cespuglio R, Proshin A, Schroeter CA et al. Understanding the role of oxidative stress, neuroinflammation and abnormal myelination in excessive aggression associated with depression: Recent input from mechanistic studies. Int J Mol Sci. 2023;24(2):915. https://doi.org/10.3390/ijms24020915.

14. Correia AS, Cardoso A, Weil N. Oxidative stress in depression: association with stress response, neuroinflammation, serotonin, neurogenesis, and synaptic plasticity. Antioxidants (Basel). 2023;12(2):470. https://doi.org/10.3390/antiox12020470.

15. Putilina MV. Endothelium as a target for new therapeutic strategies in cerebral vascular diseases. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2017;117(10):122–130. (In Russ.) https://doi.org/10.17116/jnevro2017117101122-130.

16. Sies H. Oxidative Stress: Concept and Some Practical Aspects. Antioxidants (Basel). 2020;9(9):852. https://doi.org/10.3390/antiox9090852.

17. Fındıklı E, Camkurt MA, İzci F, Karaaslan MF, Fındıklı HA, Sümer P, Kurutaş EB. The Diagnostic Value of Malondialdehyde, Superoxide Dismutase and Catalase Activity in Drug Naïve, First Episode, Non- Smoker Generalized Anxiety Disorder Patients. Clin Psychopharmacol Neurosci. 2018;16(1):88–94. https://doi.org/10.9758/cpn.2018.16.1.88.

18. Putilina MV. Modern ideas about the treatment of anxiety and depressive disorders in chronic cerebral ischemia breast cancer. RMJ. 2011;19(9):569–573. (In Russ.) Available at: https://www.rmj.ru/articles/nevrologiya/Sovremennye_predstavleniya_o_terapii_trevoghnodepressivnyh_rasstroystv_pri_hronicheskoy_ishemii_golovnogo_mozga.

19. Madireddy S, Madireddy S. Therapeutic Interventions to Mitigate Mitochondrial Dysfunction and Oxidative Stress-Induced Damage in Patients with Bipolar Disorder. Int J Mol Sci. 2022;23(3):1844. https://doi.org/10.3390/ijms23031844.

20. Jiménez-Fernández S, Gurpegui M, Garrote- Rojas D, Gutiérrez-Rojas L, Carretero MD, Correll CU. Oxidative stress parameters and antioxidants in patients with bipolar disorder: Results from a meta-analysis comparing patients, including stratification by polarity and euthymic status, with healthy controls. Bipolar Disord. 2021;23(2):117–129. https://doi.org/10.1111/bdi.12980.

21. Hinds JA, Sanchez ER. The Role of the Hypothalamus – Pituitary – Adrenal (HPA) Axis in Test-Induced Anxiety: Assessments, Physiological Responses, and Molecular Details. Stresses. 2022;2(1):146–155. https://doi.org/10.3390/stresses2010011.

22. Bortolato B, Köhler CA, Evangelou E, León-Caballero J, Solmi M, Stubbs B et al. Systematic assessment of environmental risk factors for bipolar disorder: an umbrella review of systematic reviews and meta-analyses. Bipolar Disord. 2017;19(2):84–96. https://doi.org/10.1111/bdi.12490.

23. Belleau EL, Treadway MT, Pizzagalli DA. The Impact of Stress and Major Depressive Disorder on Hippocampal and Medial Prefrontal Cortex Morphology. Biol Psychiatry. 2019;85(6):443–453. https://doi.org/10.1016/j.biopsych.2018.09.031.

24. Andreazza AC, Wang JF, Salmasi F, Shao L, Young LT. Young Specific subcellular changes in oxidative stress in prefrontal cortex from patients with bipolar disorder. J Neurochem. 2013;127(4):552–561. https://doi.org/10.1111/jnc.12316.

25. Correll CU. Oxidative stress parameters and antioxidants in patients with bipolar disorder: Results from a meta-analysis comparing patients, including stratification by polarity and euthymic status, with healthy controls. Bipolar Disord. 2021;23(2):117–129. https://doi.org/10.1111/bdi.12980.

26. Putilina MV. А role of arterial hypertension in the development of chronic disturbance of cerebral blood circulation. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2014;114(9):124–128. (In Russ.) Available at: https://www.mediasphera.ru/issues/zhurnal-nevrologii-ipsikhiatrii-im-s-s-korsakova/2014/9/031997-72982014923.

27. Riveros ME, Ávila A, Schruers K, Ezquer F. Antioxidant Biomolecules and Their Potential for the Treatment of Difficult-to- Treat Depression and Conventional Treatment-Resistant Depression. Antioxidants (Basel). 2022;11(3):540. https://doi.org/10.3390/antiox11030540.

28. Gautam M, Agrawal M, Gautam M, Sharma P, Gautam AS, Gautam S. Role of antioxidants in generalised anxiety disorder and depression. Indian J Psychiatry. 2012;54(3):244–247. https://doi.org/10.4103/00195545.102424.

29. Amr M, El- Mogy A, Shams T, Vieira K, Lakhan SE. Efficacy of vitamin C as an adjunct to fluoxetine therapy in pediatric major depressive disorder: a randomized, double- blind, placebo-controlled pilot study. Nutr J. 2013;12(1):31. https://doi.org/10.1186/1475-2891-12-31.

30. Nemets B, Mishory A, Levine J, Belmaker RH. Inositol addition does not improve depression in SSRI treatment failures. J Neural Transm (Vienna). 1999;106(7–8):795–798. https://doi.org/10.1007/s007020050200.

31. Ferraro PM, Curhan GC, Gambaro G, Taylor EN. Total, dietary, and supplemental vitamin C intake and risk of incident kidney stones. Am J Kidney Dis. 2016;67(3):400–407. https://doi.org/10.1053/j.ajkd.2015.09.005.

32. Trofimova SA, Balunov OA, Dubinina EE. Oxidative Stress and Poststroke Depression. Neurosci Behav Physiol. 2021;51:298–302. (In Russ.) https://doi.org/10.1007/s11055-021-01071-9.

33. Concerto S, Chiarenza S, Di Francesco A, Natale A, Privitera I, Rodolico A et al. Neurobiology and the use of inositol in psychiatry: a narrative review. Curr Issues Mol Biol. 2023;45(2):1762–1778. https://doi.org/10.3390/cimb45020113.

34. Ribaudo G, Bortoli M, Witt CE, Parke B, Mena S, Oselladore E et al. ROSS-cavenging Selenofluoxetine Derivatives Inhibit In Vivo Serotonin Reuptake. ACS Omega. 2022;7(10):8314–8322. https://doi.org/10.1021/acsomega.1c05567.

35. Calderón-O spina CA, Nava-Mesa MO. B Vitamins in the nervous system: Current knowledge of the biochemical modes of action and synergies of thiamine, pyridoxine, and cobalamin. CNS Neurosci Ther. 2020;26(1):5–13. https://doi.org/10.1111/cns.13207.

36. LeBlanc J (ed.). Several Dosage Forms Containing Vitamin B and Their Use in Therapy. In: B-Complex Vitamins – Sources, Intakes and Novel Applications. IntechOpen; 2021.

37. Mahdavifar B, Hosseinzadeh M, Salehi-Abargouei A, Mirzaei M, Vafa M. Dietary intake of B vitamins and their association with depression, anxiety, and stress symptoms: A cross-sectional, population-based survey. J Affect Disord. 2021;288:92–98. https://doi.org/10.1016/j.jad.2021.03.055.

38. Plantone D, Pardini M, Rinaldi G. Riboflavin in Neurological Diseases: A Narrative Review. Clin Drug Investig. 2021;41(6):513–527. https://doi.org/10.1007/s40261-021-01038-1.

39. Thompson DF, Saluja HS. Prophylaxis of migraine headaches with riboflavin: A systematic review. J Clin Pharm Ther. 2017;42(4):394–403. https://doi.org/10.1111/jcpt.12548.

40. Gasperi V, Sibilano M, Savini I, Catani MV. Niacin in the Central Nervous System: An Update of Biological Aspects and Clinical Applications. Int J Mol Sci. 2019;20(4):974. https://doi.org/10.3390/ijms20040974.

41. Amira Md Ali, Amin OH. So Antidepressant Drugs have Serious Adverse Effects, but what are the Alternatives? Nov Appro Drug Des Dev. 2018;4(3):555636. https://doi.org/10.19080/NAPDD.2018.04.555636.

42. Mukai T, Kishi T, Matsuda Y, Iwata N. A meta-analysis of inositol for depression and anxiety disorders. Hum Psychopharmacol. 2014;29(1):55–63. https://doi.org/10.1002/hup.2369.

43. Calderón-Ospina CA, Nava- Mesa MO. B Vitamins in the nervous system: Current knowledge of the biochemical modes of action and synergies of thiamine, pyridoxine, and cobalamin. CNS Neurosci Ther. 2020;26(1):5–13. https://doi.org/10.1111/cns.13207.

44. Putilina MV. A complex of B vitamins, choline and inosine in the treatment of chronic pain. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2023;123(4):114–119. (In Russ.) https://doi.org/10.17116/jnevro2023123041114.

45. Volchegorskii IA, Izarovskii BV, Shamaeva TN, Izarovskaia IV. An effect of 3-oxypyridine and succinic acid derivatives on the time of reduction of anxiety and depression symptoms in alcohol withdrawal treatment. Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(9):63–71. (In Russ.) https://doi.org/10.17116/jnevro202112109163.

46. Putilina MV. Combined neuroprotective therapy in cerebrovascular diseases cerebrovascular diseases. Vrach. 2012;(4):69–73. (In Russ.) Available at: http://neuro.rusvrach.ru/archive/vrach-2012-04-15.pdf.

47. Gudkova AN, Osinovskaia NA, Polunina AG, Guekht AB. Investigation of the effects of cytoflavin on symptoms of depression and autonomic dysfunction in patients with organic depressive disorder. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2013;113(12):50–55. (In Russ.) Available at: https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova/2013/12/031997-72982013128.

48. Kim OV, Madzhidova YN, Sharipov FR. Neuroprotective therapy in chronic cerebrovascular diseases. Russian Neurological Journal. 2021;26(4):46–49. (In Russ.) https://doi.org/10.30629/2658-7947-2021-26-4-46-4.

49. Putilina MV, Teplova NV, Bairova KI, Petrikeeva AE, Shabalina NI. The result of prospective randomized study CITADEL – the efficacy and safety of drug Cytoflavin in postcovid rehabilitation. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2021;121(10):45–51. (In Russ.) https://doi.org/10.17116/jnevro202112110145.

50. Madzhidova YN, Yusupaliev BK, Sharipov FR, Azimova NM, Mukhammadsolikh SB. Effectiveness of cytoflavin in patients with high risk development of cerebrovascular diseases. Clinical Medicine (Russian Journal). 2020;98(6):456–460. (In Russ.) https://doi.org/10.30629/00232149-2020-98-6-456-460.

51. Strokov IA, Trakhtenberg YuA, Kovalenko AL. Efficacy and safety of Cytoflavin in the treatment of diabetic polyneuropathy: results of a multicenter, double- blind, placebo- controlled, randomized CYLINDER study. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2023;123(5):100–107. (In Russ.) https://doi.org/10.17116/jnevro2023123051100.